There has been an explosion of newer HER2-directed therapies, including monoclonal antibodies, novel antibody-drug conjugates ...

A University of Kentucky Markey Cancer Center study reveals how prostate cancer cells adapt their metabolism to thrive in ...

Older Americans with metastatic breast, colorectal, lung, or prostate cancer are spending an increasing amount of time in the ...

Metastatic breast cancer treatment with the combination of PCS6422 and capecitabine (NGC-Cap) may increase the cancer-killing ...

1. Brenner A, Youssef M, Kumthekar P, et al. Rhenium (¹⁸⁶Re) obisbemeda (rhenium nanoliposome, ¹⁸⁶RNL) for the treatment of ...

For patients living with HER2-positive metastatic breast cancer, the recent FDA approval of trastuzumab deruxtecan (brand ...

Overall, tucatinib add-on to first-line maintenance therapy for HER2-positive metastatic breast cancer delayed progression by ...

Pelareorep combined with standard chemotherapy achieved a 33% objective response rate in KRAS-mutant MSS mCRC, surpassing ...

People living with metastatic breast cancer have more treatment options today than ever before. At Fred Hutch Cancer Center, we provide the latest in evidence-based care, including a wide range of ...

Preliminary Phase 2 data demonstrate PCS6422+Capecitabine increased cancer-killing metabolite exposure while maintaining comparable safety to monotherapy capecitabine VERO BEACH, Fla., Dec. 17, 2025 ...

The combination of Keytruda and Padcev is taking another major step toward securing its position as a leading therapy in the ...

Mark Cuban drug firm adds cancer biosimilar Vegzelma to its marketplace for hospitals and healthcare providers at discounted prices.